Drug profile · INN
tenofovir alafenamide + emtricitabine + elvitegravir + cobicistat
GENVOYA
tenofovir alafenamide + emtricitabine + elvitegravir + cobicistat (GENVOYA) is an FDA-listed pharmaceutical active ingredient. Associated with Gilead Sciences Pty Limited.
TGA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — tenofovir alafenamide + emtricitabine + elvitegravir + cobicistat
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.81
Quick answer
tenofovir alafenamide + emtricitabine + elvitegravir + cobicistat (GENVOYA) is an FDA-listed pharmaceutical active ingredient. Associated with Gilead Sciences Pty Limited.
Key facts
INN tenofovir alafenamide + emtricitabine + elvitegravir + cobicistat
Brand GENVOYA
Originator Gilead Sciences Pty Limited
Approval history
| Authority | Status | Date |
|---|---|---|
| TGA | approved | — |
Frequently asked questions
What is tenofovir alafenamide + emtricitabine + elvitegravir + cobicistat?
tenofovir alafenamide + emtricitabine + elvitegravir + cobicistat (GENVOYA) is an FDA-listed pharmaceutical active ingredient. Associated with Gilead Sciences Pty Limited.
What is the brand name for tenofovir alafenamide + emtricitabine + elvitegravir + cobicistat?
GENVOYA is a marketed brand name for tenofovir alafenamide + emtricitabine + elvitegravir + cobicistat. Check FDA Drugs@FDA for the current US label holder and prescribing information.